Literature DB >> 15607962

Lack of sustained regression of c-MYC-induced mammary adenocarcinomas following brief or prolonged MYC inactivation.

Robert B Boxer1, Joanne W Jang, Louis Sintasath, Lewis A Chodosh.   

Abstract

Recent studies of oncogene dependence in conditional transgenic mice have suggested the exciting possibility that transient or prolonged MYC inactivation may be sufficient for sustained reversal of the tumorigenic process. In contrast, we report here that following oncogene downregulation, the majority of c-MYC-induced mammary adenocarcinomas grow in the absence of MYC overexpression. In addition, residual neoplastic cells persist from virtually all tumors that do regress to a nonpalpable state and these residual cells rapidly recover their malignant properties following MYC reactivation or spontaneously recur in a MYC-independent manner. Thus, MYC-induced mammary tumor cells subjected to either brief or prolonged MYC inactivation remain exquisitely sensitive to its oncogenic effects and characteristically progress to a state in which growth is MYC-independent.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15607962     DOI: 10.1016/j.ccr.2004.10.013

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  88 in total

1.  Low expression of miR-let-7a promotes cell growth and invasion through the regulation of c-Myc in oral squamous cell carcinoma.

Authors:  Chunyang Luo; Jiyong Zhang; Yi Zhang; Xiao Zhang; Yinan Chen; Weimin Fan
Journal:  Cell Cycle       Date:  2020-06-28       Impact factor: 4.534

2.  MYC Inactivation Elicits Oncogene Addiction through Both Tumor Cell-Intrinsic and Host-Dependent Mechanisms.

Authors:  Dean W Felsher
Journal:  Genes Cancer       Date:  2010-06

3.  c-Myc depletion inhibits proliferation of human tumor cells at various stages of the cell cycle.

Authors:  H Wang; S Mannava; V Grachtchouk; D Zhuang; M S Soengas; A V Gudkov; E V Prochownik; M A Nikiforov
Journal:  Oncogene       Date:  2007-10-01       Impact factor: 9.867

4.  The Myc and Ras Partnership in Cancer: Indistinguishable Alliance or Contextual Relationship?

Authors:  Wadie D Mahauad-Fernandez; Dean W Felsher
Journal:  Cancer Res       Date:  2020-07-30       Impact factor: 12.701

5.  N-myc alters the fate of preneoplastic cells in a mouse model of medulloblastoma.

Authors:  Jessica D Kessler; Hiroshi Hasegawa; Sonja N Brun; Brian A Emmenegger; Zeng-Jie Yang; John W Dutton; Fan Wang; Robert J Wechsler-Reya
Journal:  Genes Dev       Date:  2009-01-15       Impact factor: 11.361

Review 6.  The role of supercoiling in transcriptional control of MYC and its importance in molecular therapeutics.

Authors:  Tracy A Brooks; Laurence H Hurley
Journal:  Nat Rev Cancer       Date:  2009-11-12       Impact factor: 60.716

7.  Epigenetic silencing of tumor suppressor Par-4 promotes chemoresistance in recurrent breast cancer.

Authors:  Nathaniel W Mabe; Douglas B Fox; Ryan Lupo; Amy E Decker; Stephanie N Phelps; J Will Thompson; James V Alvarez
Journal:  J Clin Invest       Date:  2018-08-27       Impact factor: 14.808

8.  Mad2-induced chromosome instability leads to lung tumour relapse after oncogene withdrawal.

Authors:  Rocio Sotillo; Juan-Manuel Schvartzman; Nicholas D Socci; Robert Benezra
Journal:  Nature       Date:  2010-02-21       Impact factor: 49.962

9.  Redefining the expression and function of the inhibitor of differentiation 1 in mammary gland development.

Authors:  Radhika Nair; Simon Junankar; Sandra O'Toole; Jaynish Shah; Alexander D Borowsky; J Michael Bishop; Alexander Swarbrick
Journal:  PLoS One       Date:  2010-08-03       Impact factor: 3.240

Review 10.  Unlocking the power of cross-species genomic analyses: identification of evolutionarily conserved breast cancer networks and validation of preclinical models.

Authors:  Christina N Bennett; Jeffrey E Green
Journal:  Breast Cancer Res       Date:  2008-09-11       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.